Pacific Edge slumps 89.9% on Novitas decision

Pacific Edge slumps 89.9% on Novitas decision
The company still believes that it can still deliver. (Image: Pacific Edge).
Rebecca Howard
Shares of Pacific Edge plunged 89.9% on news that Medicare coverage of Cxbladder tests in the US is expected to cease from July 17.The shares resumed trading at 5 cents, having been halted on Tuesday at 49.5 cents while management worked through the implications of the decision.That wiped out $360.6 million of value as investors put a market price of $40.5m on Pacific Edge.  Over the coming days Pacific Edge will seek to explore all available legal options, including a potential appeal, with its US-based lawyers, the company said.A so-call...

More Markets

Major stock moves expected as index reshuffles hit markets
Markets

Major stock moves expected as index reshuffles hit markets

Analysts are anticipating the week will end with significant volume and volatility.

Sharesies’ app affected by more than hour-long outage
Finance

Sharesies’ app affected by more than hour-long outage

Sharesies portfolio app was down for more than an hour, frustrating US-focused investors.

Co-ops last five times longer than limited liability companies - report
Primary Sector

Co-ops last five times longer than limited liability companies - report

Top 30 co-ops and mutuals made $51.9b revenue in 2024, 12.5% of GDP.

Nothing to see here – Aussie regulator slams ANZ
Finance

Stock & Trade: Nothing to see here – Aussie regulator slams ANZ

FMA confirms eight complaints over NZ bond trading, but no action was taken.